KLK3 and benign prostatic hyperplasia: To reduce unnecessary prostate biopsies in benign prostatic hyperplasia patients, some biomarkers such as PSA and fPSA can be used in guiding biopsies, but the lack of sensitivity and specificity restrict their use for detecting prostate cancer alone.